Advertisement

Clinical Classification and Incidence of Malignant Hyperthermia in Japan

  • Osafumi Yuge
  • Michio Morio
  • Hirosato Kikuchi
  • Keiko Mukaida
  • Yasuhiro Maehara
  • Masakazu Nakao
  • Masashi Kawamoto
Conference paper

Abstract

Denborough and Lovell [1] first described malignant hyperthermia (MH) as an inherited syndrome in 1960. At present, it is generally accepted that MH is triggered by many anesthetics. Succinylcholine chloride (SCC) and volatile anesthetics have been especially implicated as important triggering drugs [2,3]. With these triggering drugs, induced hypermetabolism produces tachycardia, increased O2 consumption and CO2 production, premature ventricular contraction, hypotension and hypertension, cyanosis, tachypnea, muscle rigidity, and hyperthermia as the signs of MH. Also seen as complications of MH are electrolyte imbalances, myoglobinuria, hyperkalemia, creatine phosphokinase (CPK) elevation, impaired coagulation, renal failure, and severe metabolic and respiratory acidosis.

Keywords

Volatile Anesthetic Malignant Hyperthermia Malignant Hyperthermia Muscle Rigidity Malignant Hyperthermia Susceptibility 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Denborough MA, Lovell RRH (1960) Anesthetic deaths in a family. Lancet 2: 45CrossRefGoogle Scholar
  2. 2.
    Gronert GA (1980) Malignant hyperthermia. Anesthesiology 53: 395–423PubMedCrossRefGoogle Scholar
  3. 3.
    Kaplan RF (1991) Malignant hyperthermia. In: 42th annual reference course lectures the American Society of Anesthiologists (ASA), p 2311Google Scholar
  4. 4.
    Britt BA, Kalow W (1970) Malignant hyperthermia: statistical review. Can Anesth Soc J 17: 293–315CrossRefGoogle Scholar
  5. 5.
    Ellis FR, Halsall PJ (1980) Malignant hyperpyrexia. Br J Hosp Med 24: 318–327PubMedGoogle Scholar
  6. 6.
    Ording H (1985) Incidence of malignant hyperthermia in Denmark. Anesth Analg 64: 700–704PubMedGoogle Scholar
  7. 7.
    Morio M, Kikuchi H, Yuge O, et al (1987) Incidence of malignant Hyperthermia. In: Proceedings, 7th European congress of anesthesiologists, vol III, pp 82–88Google Scholar
  8. 8.
    Kikuchi H, Matsui I, Morio M (1987) Diagnosis of malignant hyperthermia in Japan by the skinned fiber test. In: Britt BA (ed) Malignant hyperthermia. Nijhoff, Dordrecht, pp 279–294CrossRefGoogle Scholar
  9. 9.
    Nakao M, Mukaida K, Kubota M, et al (1991) Variable incidences of fulminant malignant hyperthermia in Japan. In: Proceedings, 14th Japan MH Sympo., pp 83–85Google Scholar
  10. 10.
    Strazis KP, Fox AW (1993) Malignant hyperthermia: a review of published cases. Anesth Analg, 77: 297–304PubMedGoogle Scholar
  11. 11.
    Heilinger D, Donner E, Sauberer A, et al (1994) Malignant hyperthermia in Austria 1984–1993. In: 3rd international symposium on malignant hyperthermia, abstract 23Google Scholar
  12. 12.
    Kalow W, Britt BA, Terreau ME, et al (1970) Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet 2: 895–898PubMedCrossRefGoogle Scholar
  13. 13.
    Ellis FR, Harriman DGF, Keaney NP, et al (1971) Halothane-induced muscle contracture as a cause of hyperpyrexia. Br J Anaesth 43: 721–722PubMedGoogle Scholar
  14. 14.
    Kalow W, Britt BA, Richter A (1977) The caffeine test of isolated human muscle in relation to malignant hyperthermia. Can Anaesth Soc J 24: 678–694PubMedCrossRefGoogle Scholar
  15. 15.
    Kawana Y, lino M, Horiuti K, et al (1992) Acceleration in calcium-induced calcium release in the biopsied muscle fibers from patients with malignant hyperthermia. Biomed Res 13 (4): 287–297Google Scholar
  16. 16.
    Matsui K, Fujioka Y, Mukaida K, et al (1989) Comparative study on in vitro diagnosis by the skinned fiber test and clinical diagnosis of malignant hyperthermia. Masui (Jpn J Anesthesiol) 38: 195–201Google Scholar
  17. 17.
    Endo M, Yagi S, Ishizuka T, et al (1983) Changes in the Ca-induced Ca release mechanism in the sarcoplasmic reticulum of the muscle from a patient with malignant hyperthermia. Biomed Res 4: 83–92Google Scholar
  18. 18.
    McCarthy TV, Healy JMS, Heffron JJA, et al (1990) Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12–13.2. Nature 343: 562–564PubMedCrossRefGoogle Scholar
  19. 19.
    Gillard EF, Otsu K, Fujii J, et al (1991) A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 11: 751–755PubMedCrossRefGoogle Scholar
  20. 20.
    Larach MG, Localio AR, Allen GC, et al (1994) A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 80: 771–779PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1996

Authors and Affiliations

  • Osafumi Yuge
    • 1
  • Michio Morio
    • 2
  • Hirosato Kikuchi
    • 3
  • Keiko Mukaida
    • 1
  • Yasuhiro Maehara
    • 1
  • Masakazu Nakao
    • 1
  • Masashi Kawamoto
    • 1
  1. 1.Department of Anesthesiology and Critical Care MedicineHiroshima University School of MedicineHiroshima, 734Japan
  2. 2.Chugoku Rosai General HospitalKure, HiroshimaJapan
  3. 3.First Department of AnesthesiologyToho University School of MedicineTokyo, 143Japan

Personalised recommendations